These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 33420186)
21. Tackling COVID-19: identification of potential main protease inhibitors via structural analysis, virtual screening, molecular docking and MM-PBSA calculations. Al-Shar'i NA J Biomol Struct Dyn; 2021 Oct; 39(17):6689-6704. PubMed ID: 32734828 [TBL] [Abstract][Full Text] [Related]
22. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297 [TBL] [Abstract][Full Text] [Related]
23. Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 M Ahamad S; Kanipakam H; Birla S; Ali MS; Gupta D Eur J Pharmacol; 2021 Jan; 890():173664. PubMed ID: 33131721 [TBL] [Abstract][Full Text] [Related]
24. Identification of Pyrazole Derivatives of Usnic Acid as Novel Inhibitor of SARS-CoV-2 Main Protease Through Virtual Screening Approaches. Roney M; Singh G; Huq AKMM; Forid MS; Ishak WMBW; Rullah K; Aluwi MFFM; Tajuddin SN Mol Biotechnol; 2024 Apr; 66(4):696-706. PubMed ID: 36752937 [TBL] [Abstract][Full Text] [Related]
27. An efficient eco-friendly, simple, and green synthesis of some new spiro-N-(4-sulfamoyl-phenyl)-1,3,4-thiadiazole-2-carboxamide derivatives as potential inhibitors of SARS-CoV-2 proteases: drug-likeness, pharmacophore, molecular docking, and DFT exploration. El-Saghier AM; Enaili SS; Abdou A; Kadry AM Mol Divers; 2024 Feb; 28(1):249-270. PubMed ID: 37946070 [TBL] [Abstract][Full Text] [Related]
28. Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants. Muhammad I; Rahman N; Gul-E-Nayab ; Niaz S; Basharat Z; Rastrelli L; Jayanthi S; Efferth T; Khan H Comput Biol Med; 2021 Jun; 133():104362. PubMed ID: 33894500 [TBL] [Abstract][Full Text] [Related]
29. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539 [TBL] [Abstract][Full Text] [Related]
37. Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment. Liu J; Xu L; Guo W; Li Z; Khan MKH; Ge W; Patterson TA; Hong H Exp Biol Med (Maywood); 2023 Nov; 248(21):1927-1936. PubMed ID: 37997891 [TBL] [Abstract][Full Text] [Related]
38. Targeting two potential sites of SARS-CoV-2 main protease through computational drug repurposing. Prakash A; Borkotoky S; Dubey VK J Biomol Struct Dyn; 2023 Apr; 41(7):3014-3024. PubMed ID: 35266856 [TBL] [Abstract][Full Text] [Related]
39. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment. Elzupir AO Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540 [TBL] [Abstract][Full Text] [Related]